Furthermore, FAK inhibitors, which are currently in clinical trials for other tumors, may provide an effective therapeutic opportunity to treat pancreatic cancer without destroying nearby normal tissue. The gene discussed is PTK2; the disease is familial pancreatic carcinoma.